Summary: Evidence increasingly indicates that immune-mediated damage, rather than direct viral invasion of brain cells, likely explains many of the long-term neurological effects reported after COVID-19.
Source: Yale
Although COVID-19 is fundamentally a respiratory disease, its effects frequently extend to the nervous system. Clinicians and researchers have documented a wide range of neurologic and psychiatric complications linked to SARS-CoV-2 infection—some appearing during acute illness and others persisting as part of long COVID.
In a Perspective published in Science on January 20, Serena Spudich, MD, Gilbert H. Glaser Professor of Neurology at Yale, reviews current understanding of how COVID-19 affects the brain and highlights the urgent need to identify underlying mechanisms so targeted therapies can be developed.
Spudich explains that the neurological consequences of SARS-CoV-2 infection are remarkably varied. Even people with otherwise mild respiratory symptoms can experience cognitive fog, confusion, excessive sleepiness, severe headaches, and abnormal skin sensations. More severe infections have been associated with stroke and other acute neurologic events.
Early in the pandemic, researchers feared that SARS-CoV-2 might directly invade and replicate in brain tissue, causing neuronal death and structural damage. However, Spudich and colleagues summarize a growing body of evidence suggesting that direct viral invasion of the central nervous system is uncommon. Studies of cerebrospinal fluid (CSF) and autopsy examinations have rarely identified viral RNA or intact viral particles in the brain.
Instead, many investigations point to immune-mediated processes as the primary drivers of neurologic dysfunction. During infection the immune system releases inflammatory molecules intended to control pathogens; in some individuals these responses appear to become dysregulated. Elevated markers of immune activation and inflammation have been detected in the CSF and brain tissue of affected patients, which can interfere with neuronal signaling and brain function even without detectable virus.
Autoimmunity is another potential mechanism under study. In certain cases the immune response intended to target the virus may mistakenly recognize components of the nervous system as foreign and mount an attack. Such autoimmune reactions can affect either central structures in the brain or peripheral nerves, producing a spectrum of neurologic and psychiatric symptoms.
Long COVID—where symptoms persist for months after the acute infection resolves—poses particular diagnostic and therapeutic challenges. Many patients report ongoing problems with attention, memory, mood, and sensory disturbances despite normal results on routine clinical tests. The heterogeneity of long COVID presentations complicates research efforts and suggests multiple, potentially overlapping biological pathways may be responsible.
Spudich emphasizes that persistent neuroinflammation initiated during acute infection could explain prolonged symptoms in some people, while chronic autoimmune processes might account for others. At present, robust evidence distinguishing these possibilities is limited, underlining the need for more detailed, multidisciplinary studies that combine immunology, neurology, and advanced imaging.
Research teams at Yale are applying tools developed from decades of work on HIV-related neurologic disease to better characterize COVID-19’s effects on the nervous system. By analyzing cells and proteins present in the CSF and correlating these molecular signatures with structural and functional MRI findings, investigators aim to define biological subtypes—so-called biological phenotypes—of neurologic post-COVID conditions. Identifying clear biomarkers would enable more precise diagnosis and guide the development of targeted treatments, such as therapies to reduce harmful inflammation or modulate autoimmune responses.
Spudich and her colleagues, including Shelli Farhadian, MD, PhD, and Lindsay McAlpine, MD, BSc, are studying how immune-related changes in the CSF and brain differ between people with persistent symptoms after COVID-19 and those who recover without lingering issues. Their work seeks to translate laboratory and imaging findings into clinical strategies that can restore function and quality of life for affected individuals.
Understanding whether long COVID increases the risk of future neurodegenerative disorders such as dementia is another important area of inquiry. Currently there are limited long-term data, so prospective follow-up and larger population studies will be essential to determine any elevated risks and to identify opportunities for early intervention.
Spudich notes that the societal and personal impacts of persistent neurologic symptoms are substantial: many people with long COVID experience reduced ability to work and a markedly diminished quality of life. Clarifying the biological causes of these symptoms is a critical step toward developing effective treatments and preventing additional downstream consequences for the nervous system.
“There are powerful research tools now—sensitive immunologic assays, methods to detect tiny viral fragments, and advanced neuroimaging—that can help us map how COVID-19 changes the brain,” Spudich says. “With sustained effort, funding, and collaboration across specialties, we expect to uncover mechanisms and translate those insights into therapies that relieve suffering and restore function.”
About this COVID-19 research news
Author: Bess Connolly
Source: Yale
Contact: Bess Connolly – Yale
Image: The image is in the public domain
Original Research: The findings will appear in Science